Progression-free, disease-free, and recurrence-free survivals as surrogate in NSCLC perioperative chemotherapy trials
Not Applicable
- Conditions
- SCLC
- Registration Number
- JPRN-UMIN000052558
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not specified
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoints consist of the correlation between hazard ratios (HRs) of surrogate endpoints and overall survival (OS). The surrogates, namely DFS, RFS, and PFS, will be evaluated collectively for the primary endpoints. DFS, RFS, and PFS will be assessed specifically as part of the subgroup analysis.
- Secondary Outcome Measures
Name Time Method